LSE:GSKPharmaceuticals
GSK Ends Alector Alzheimer’s Bet And Refocuses On ADC Oncology Potential
GSK (LSE:GSK) and Alector have ended their Alzheimer’s drug partnership after repeated clinical failures.
The decision follows lack of efficacy in key trials within a major neurodegeneration program.
Separately, GSK has halted an external antibody drug conjugate collaboration following clinical issues and FDA holds.
The company is now concentrating on internally developed and in licensed antibody drug conjugates for oncology.
For readers tracking LSE:GSK, this marks a clear change in how...